MedPath

Melphalan

Generic Name
Melphalan
Brand Names
Alkeran, Evomela, Phelinun, Pepaxti
Drug Type
Small Molecule
Chemical Formula
C13H18Cl2N2O2
CAS Number
148-82-3
Unique Ingredient Identifier
Q41OR9510P

Overview

Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.

Background

Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.

Indication

Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary. Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.

Associated Conditions

  • Multiple Myeloma (MM)
  • Unresectable Liver Metastasis
  • Unresectable Ovarian Cancer (Epithelial)

Clinical Trials

View More Clinical Trials

Sign in to access the complete clinical trial database with detailed study information.

Title
Posted
Study ID
Phase
Status
Sponsor
2005/08/23
Phase 2
Completed
2005/07/21
Phase 2
Terminated
2005/06/14
Phase 3
Active, not recruiting
2005/06/03
Phase 1
Completed
2005/06/03
Phase 1
Completed
City of Hope Medical Center
2005/03/04
Phase 1
Completed
2005/02/08
Phase 2
Completed
2004/11/09
Phase 2
Completed
Delcath Systems Inc.
2004/09/13
Phase 2
Completed
2004/09/01
Phase 1
Completed

FDA Approved Products

View More FDA Products

Sign in to access additional FDA-approved products with detailed regulatory information.

Product Name
Manufacturer
Route
Strength
Approved
NDC Code

No FDA products found

No FDA products found for this drug

EMA Approved Products

View More EMA Products

Sign in to access additional EMA-approved products with authorization details.

Medicine Name
EMA Number
Auth. Holder
Country
Drug Type
Status
Issued
Opinion
Revision

No EMA products found

No EMA products found for this drug

HSA Approved Products

View More HSA Products

Sign in to access additional HSA-approved products with regulatory information.

Product Name
Manufacturer
Dosage Form
Strength
Approved
Approval No.

No HSA products found

No HSA products found for this drug

NMPA Approved Products

View More NMPA Products

Sign in to access additional NMPA-approved products with approval information.

Product Name
Approval No.
Manufacturer
Dosage Form
Trade Name
Strength
Type
Status
Date
Import

No NMPA products found

No NMPA products found for this drug

PPB Approved Products

Product Name
Registration Code
Company
Category
Sale Type
Reg. Date

No PPB products found

No PPB products found for this drug

TGA Approved Products

View More TGA Products

Sign in to access additional TGA-approved products with licensing information.

Product Name
ARTG ID
Sponsor
Status
Reg. Date
Ingredient

No TGA products found

No TGA products found for this drug

© Copyright 2025. All Rights Reserved by MedPath